Ribomic Inc. (TYO:4591)

Market Cap	4.47B +3.3%
Revenue (ttm)	7.50M +650.0%
Net Income	-1.19B
EPS	-22.69
Shares Out	56.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	560,600
Open	79.00
Previous Close	79.00
Day's Range	76.00 - 79.00
52-Week Range	57.00 - 120.00
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Ribomic

Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glauco...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 25
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4591

Financial Performance

In fiscal year 2026, Ribomic's revenue was 3.00 million, an increase of 50.00% compared to the previous year's 2.00 million. Losses were -1.15 billion, 12.5% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 16, 2026

Data Sources Report a data error